Meibomian Gland Dysfunction Treatment Using Keratolytic Agents
Summary
USPTO inventors Yair Alster, Omer Rafaeli, Kirsten Angela Macfarlane, Cary Reich, Shimon Amselem, and Doron Friedman filed Application US20260108533A1 on August 29, 2025 (Application No. 19315391), published April 23, 2026. The application discloses topical compositions comprising keratolytic agents such as salicylic acid or selenium disulfide for treating meibomian gland dysfunction via administration to the eyelid margin. Pharmaceutical companies developing ophthalmic or dermatologic therapeutics should review the disclosed claims for freedom-to-operate implications and competitive landscape assessment.
“Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published Patent Application US20260108533A1 on April 23, 2026, establishing a priority date of August 29, 2025 for compositions and methods treating meibomian gland dysfunction using keratolytic agents including salicylic acid, selenium disulfide, and related compounds. The published application discloses topical formulations for administration to the eyelid margin or surrounding areas to provide therapeutic benefit to patients.
Pharmaceutical companies and healthcare providers involved in ophthalmic or dermatologic therapeutic development should monitor this application's prosecution for freedom-to-operate implications. Third parties may request continued examination or submit prior art during the statutory response period. Patent rights, if granted, would provide exclusionary rights to the disclosed compositions and methods of treatment.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION
Application US20260108533A1 Kind: A1 Apr 23, 2026
Inventors
Yair ALSTER, Omer RAFAELI, Kirsten Angela MACFARLANE, Cary REICH, Shimon AMSELEM, Doron FRIEDMAN
Abstract
Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
CPC Classifications
A61K 31/60 A61K 8/22 A61K 8/23 A61K 9/0048 A61K 9/06 A61K 31/122 A61K 31/17 A61K 31/19 A61K 31/327 A61K 31/4015 A61K 31/555 A61K 33/04 A61K 35/04 A61K 9/0014
Filing Date
2025-08-29
Application No.
19315391
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.